Calamos Advisors LLC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 12 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.4%.

Quarter-by-quarter ownership
Calamos Advisors LLC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$4,903,450
+22.6%
5,000,0000.0%0.02%
+25.0%
Q2 2023$3,998,350
-3.8%
5,000,0000.0%0.02%0.0%
Q1 2023$4,156,550
+9.8%
5,000,0000.0%0.02%
+11.1%
Q4 2022$3,784,450
+0.2%
5,000,0000.0%0.02%
+5.9%
Q3 2022$3,777,000
+17.7%
5,000,0000.0%0.02%
+21.4%
Q2 2022$3,209,000
+4.6%
5,000,0000.0%0.01%
+16.7%
Q1 2022$3,068,000
+1.9%
5,000,0000.0%0.01%
+9.1%
Q4 2021$3,012,000
-0.6%
5,000,0000.0%0.01%
-15.4%
Q3 2021$3,030,000
-11.4%
5,000,0000.0%0.01%
-18.8%
Q2 2021$3,421,000
+6.2%
5,000,0000.0%0.02%
-11.1%
Q1 2021$3,220,000
+6.1%
5,000,0000.0%0.02%0.0%
Q4 2020$3,036,000
-12.4%
5,000,0000.0%0.02%
-18.2%
Q3 2020$3,465,000
-3.8%
5,000,0000.0%0.02%
-12.0%
Q2 2020$3,602,000
-17.1%
5,000,0000.0%0.02%
-26.5%
Q1 2020$4,345,000
-34.7%
5,000,0000.0%0.03%
+3.0%
Q4 2019$6,649,000
+46.6%
5,000,0000.0%0.03%
+32.0%
Q3 2019$4,537,000
-9.2%
5,000,0000.0%0.02%
-10.7%
Q2 2019$4,998,0005,000,0000.03%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q2 2021
NameSharesValueWeighting ↓
Worth Venture Partners, LLC 5,814,000$5,191,0003.20%
DLD Asset Management, LP 12,500,000$11,219,0000.70%
Senvest Management, LLC 5,000,000$4,345,0000.51%
Context Capital Management, LLC 985,000$863,0000.49%
LINDEN ADVISORS LP 30,755,000$26,983,0000.48%
SSI INVESTMENT MANAGEMENT LLC 5,896,000$5,014,0000.44%
BOOTHBAY FUND MANAGEMENT, LLC 4,386,000$3,812,0000.32%
ADVENT CAPITAL MANAGEMENT /DE/ 16,582,000$14,449,0000.31%
CSS LLC/IL 3,825,000$3,410,0000.27%
Polar Asset Management Partners Inc. 13,000,000$11,372,0000.23%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders